A total of 121 men with complicated infections caused by ,-lactamase-negative Neisseria gonorrhoeae were included in this study. They were randomly assigned to regimens of either cefmenoxime (1.0 g) or procaine penicillin G (4.8 x 106 U) intramuscularly. Only the penicillin group also took 1.0 g of probenecid orally. A total of 99 patients completed the study, providing data from 108 infected sites. In the cefmenoxime group, there were 49 urethral, 1 rectal, and 2 pharyngeal infections; in the penicillin group, there were 49 urethral, 4 rectal, and 3 pharyngeal infections. In the cefmenoxime group, all except one urethral infection were eradicated. This patient admitted having had sexual intercourse during the follow-up period and was considered to be reinfected. In the penicillin group, all except one pharyngeal infection were cured. No adverse reactions were noted in either group. In this study, cefmenoxime was as effective as penicillin in the treatment of gonococcal urethritis in men.
Cefmenoxime (SCE-1365, A-50912), a new semisynthetic cephalosporin antimicrobial agent, is highly active in vitro against Neisseria gonorrhoeae (6) . It inhibits all isolates, regardless of P-lactamase activity, at a concentration of 0.015 ,ug/ml (6) . The peak serum concentration of cefmenoxime after a 1.0-g intramuscular (i.m.) injection has been reported to be 24.0 ± 2.1 ,ug/ml, with a half-life of 99.6 ± 7.3 min (J. Guibert, M. D. Kitzis, C. Yvelin, L. Peterescou, and A. Bryskier, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 21st, Chicago, Ill., abstr. no. 606, 1981) . In this study, we compared the efficacy and safety of cefmenoxime with those of penicillin in the single-dose treatment of uncomplicated gonococcal infections. To our knowledge, clinical studies to assess the efficacy of cefmenoxime in the treatment of gonorrhea have not been previously reported. The minimal inhibitory concentrations of cefmenoxime and penicillin were determined for 126 N. gonorrhoeae isolates from this study population. Ninety percent of the clinical isolates were inhibited by <0.01 ,ug of cefmenoxime and <0.32 ,ug of penicillin per ml (Fig. 1) A very small number of rectal and pharyngeal gonococcal infections were treated in this study. Although cefmenoxime cured these infected sites, further clinical trials are needed before conclusions can be drawn.
MATERIALS
All of the infections in this study were caused by 3-lactamase-negative N. gonorrhoeae. When compared with penicillin, cefmenoxime showed 32-fold greater in vitro activity against these isolates. Cefmenoxime has also been shown to be highly active in vitro against P-lactamasepositive N. gonorrhoeae (6) .
In summary, cefmenoxime appears to be an effective antimicrobial agent in treating gonococcal urethritis caused by (-lactamase-negative strains. Clinical trials to verify the efficacy of cefmenoxime in treating ,B-lactamase-positive N. gonorrhoeae infections are indicated.
